We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+43.87%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.69B
AUM Growth
+$1.28B
Cap. Flow
+$331M
Cap. Flow %
4.95%
Top 10 Hldgs %
72.51%
Holding
39
New
–
Increased
16
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$156M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$47.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$44.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29M
5
APLS
Apellis Pharmaceuticals
APLS
+$26.5M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.6M
2
UTHR icon
United Therapeutics
UTHR
+$15.5M
3
RLAY icon
Relay Therapeutics
RLAY
+$8.95M
4
AMRN
Amarin Corp
AMRN
+$6.54M
5
KURA icon
Kura Oncology
KURA
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$824M
$38.5M 0.58%
3,105,000
-420,000
-12% -$6.11M
WHWK
27
Whitehawk Therapeutics
WHWK
$232M
$36.6M 0.55%
2,849,402
– –
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.55B
$34.7M 0.52%
750,000
– –
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.33B
$32.9M 0.49%
4,325,000
+961,667
+29% +$8.01M
PMVP icon
30
PMV Pharmaceuticals
PMVP
$62.9M
$26.6M 0.4%
3,060,000
– –
DSGN icon
31
Design Therapeutics
DSGN
$862M
$23.3M 0.35%
2,272,222
+50,000
+2% +$678K
AMLX icon
32
Amylyx Pharmaceuticals
AMLX
$2.7B
$23.3M 0.35%
630,000
-20,000
-3% -$710K
MRNS
33
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.5M 0.19%
3,150,000
– –
TNGX icon
34
Tango Therapeutics
TNGX
$4.72B
$11.9M 0.18%
1,640,000
+90,000
+6% +$633K
FENC icon
35
Fennec Pharmaceuticals
FENC
$377M
$11.5M 0.17%
1,200,000
– –
IOBT
36
DELISTED
IO Biotech
IOBT
$4.73M 0.07%
2,055,883
– –
AMRN
37
Amarin Corp
AMRN
$301M
– –
-300,000
Closed -$6.54M
BCAB icon
38
BioAtla
BCAB
$5.53M
– –
-11,500
Closed -$4.43M
RLAY icon
39
Relay Therapeutics
RLAY
$4.3B
– –
-400,000
Closed -$8.95M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Avoro Capital Advisors held 39 positions worth $6.69B, up 24% from $5.41B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $331M of net new capital in Q4 2022, adding to 16 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $15.6M trimmed.

  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $156M increase.
  • Avoro Capital Advisors's biggest Q4 2022 reduction was Iovance Biotherapeutics, cutting an estimated $15.6M.
  • Avoro Capital Advisors fully exited Relay Therapeutics in Q4 2022, selling an estimated $8.95M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $6.69B portfolio in Q4 2022.
  • Avoro Capital Advisors opened 0 new positions and closed 3 in Q4 2022.
  • Avoro Capital Advisors's portfolio value rose 24% quarter-over-quarter to $6.69B.

Based on Avoro Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.